Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06388174

Idiopathic Generalized Epilepsy Syndromes

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.

According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Epilepsy, Idiopathic Generalized Nervous System Diseases

Age range

4 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, 310000, China

Location status: Recruiting

Location contact

Chunhong Shen

CONTACT

[email protected]

+86 0571 87783872

About this study

the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
  • Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
  • Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
  • Sign the informed consent forms.

Exclusion criteria

  • Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
  • Lost to follow-up

Treatment and study plan

Primary outcomes

  1. The proportion of drug-resistent epilepsy

    Time frame: through study completion, an average of 1 year

    We defined drug-resistant cases as those patients who have failed two or more trials of broad-spectrum ASMs or those otherwise indicated in IGE syndromes

  2. The proportion of seizure freedom

    Time frame: through study completion, an average of 1 year

    We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition

Secondary outcomes

  1. The proportion of psychiatric comorbidity

    Time frame: through study completion, an average of 1 year

    The psychiatric comorbidities mainly include anxiety and depression, which are evaluated by Hamilton anxiety scale and Hamilton depression scale, respectively.

  2. The proportion of psychosocial outcome

    Time frame: through study completion, an average of 1 year

    such as university entrance, marry

  3. The proportion of seizure relapse after antiseizure medication withdrawn

    Time frame: through study completion, an average of 1 year

    Antiseizure medication withdrawn should be recommended by epilepsy experts

Study contacts

Contact information is provided by the study sponsor or research team.

Chunhong Shen

CONTACT

[email protected]

+86 0571 87783872

Sponsors and collaborators

Lead sponsor

Shen Chun-Hong

Other

Registry information

Official study title

Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes

Important dates

Study start
2023
Primary completion
2026
Study completion
2033
First posted
Apr 29, 2024
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.